Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR33532819

— · E

bb2555dc-ff58-516c-92cb-4b9effead421

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.550
  • G2M_CHECKPOINT+0.520
  • MYC_TARGETS_V1+0.490
  • MITOTIC_SPINDLE+0.420
  • PROTEIN_SECRETION+0.380
  • SPERMATOGENESIS+0.260
  • DNA_REPAIR+0.240
  • UNFOLDED_PROTEIN_RESPONSE+0.210
  • PANCREAS_BETA_CELLS+0.180
  • ANDROGEN_RESPONSE+0.160

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.390
  • INTERFERON_GAMMA_RESPONSE-0.380
  • COAGULATION-0.320
  • TNFA_SIGNALING_VIA_NFKB-0.320
  • IL6_JAK_STAT3_SIGNALING-0.310
  • INFLAMMATORY_RESPONSE-0.300
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
  • IL2_STAT5_SIGNALING-0.290
  • ALLOGRAFT_REJECTION-0.260
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1797280
lung-landscapes@6
—cohortSC0.909
2SJEPD030795_D3.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.900
3BS_8QB4S4VA
brain-umap@2
Embryonal tumors—0.897
4SJEPD031150_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.896
5TCGA-78-7155-01A-11R-2039-07
lung-landscapes@6
—cohortMD10.892
6242a1034-4aae-46f8-a40d-91710af30d0a
colon-landscapes@1
——0.889
7R375
bladder-landscape@3
——0.889
8msclc591T1_S51.txt
lung-landscapes@6
—cohortSC0.887
9TCGA-BH-A204-01A-11R-A157-07
breast-umap@18
—B0.885
10BS_EFE4YEK3
medullo-epn-umap@date-based
MedMedulloblastoma0.879

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 16 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.550Inavolisib— uncovered
G2M_CHECKPOINT0.520Inavolisib— uncovered
MYC_TARGETS_V10.490Inavolisib— uncovered
MITOTIC_SPINDLE0.420Inavolisib— uncovered
PROTEIN_SECRETION0.380Remibrutinib— uncovered
SPERMATOGENESIS0.260Inavolisib— uncovered
DNA_REPAIR0.240Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.210Idelalisib— uncovered
PANCREAS_BETA_CELLS0.180Cobimetinib— uncovered
ANDROGEN_RESPONSE0.160Inavolisib— uncovered
MTORC1_SIGNALING0.160Inavolisib— uncovered
HEME_METABOLISM0.140Temsirolimus— uncovered
MYC_TARGETS_V20.120Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
TGF_BETA_SIGNALING0.070Inavolisib— uncovered
UV_RESPONSE_DN0.070Inavolisib— uncovered